Search Results

OmniSeq®, an innovator in next generation sequencing in oncology, announced the New York State Department of Health’s Clinical Laboratory Evaluation Program has approved the OmniSeq INSIGHTSM test.

Labcorp (NYSE: LH), and OmniSeq, a CAP-accredited, molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, today announced the launch of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology.

GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp’s OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors.

OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the company has received the International Organization for Standards (ISO) 13485:2016 certification for its Quality Management Systems (QMS)

OmniSeq®, an innovator in next generation sequencing in oncology, today announced its collaboration with the University of Pittsburgh Medical Center (UPMC) to employ its RNA sequencing (RNA-seq) gene expression profile assay for selecting immunotherapy combinations for patients in a Phase II clinical trial for patients with Recurrent/Metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance® comprehensive genomic and immune profiling assay to detect the presence of rare alterations in the RET gene in the tumors of some patients with non-small cell lung cancer (NSCLC) and thyroid cancer

OmniSeq, Inc.® announced it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial